File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma

TitleThe diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma
Authors
Keywordsimmunotherapy
microglia
monocyte-derived macrophages
recurrent glioblastoma
single-cell
tumor microenvironment
Issue Date4-Sep-2023
PublisherFrontiers Media
Citation
Frontiers in Immunology, 2023, v. 14 How to Cite?
Abstract

Despite tremendous efforts to exploit effective therapeutic strategies, most glioblastoma (GBM) inevitably relapse and become resistant to therapies, including radiotherapy and immunotherapy. The tumor microenvironment (TME) of recurrent GBM (rGBM) is highly immunosuppressive, dominated by tumor-associated macrophages (TAMs). TAMs consist of tissue-resident microglia and monocyte-derived macrophages (MDMs), which are essential for favoring tumor growth, invasion, angiogenesis, immune suppression, and therapeutic resistance; however, restricted by the absence of potent methods, the heterogeneity and plasticity of TAMs in rGBM remain incompletely investigated. Recent application of single-cell technologies, such as single-cell RNA-sequencing has enabled us to decipher the unforeseen diversity and dynamics of TAMs and to identify new subsets of TAMs which regulate anti-tumor immunity. Here, we first review hallmarks of the TME, progress and challenges of immunotherapy, and the biology of TAMs in the context of rGBM, including their origins, categories, and functions. Next, from a single-cell perspective, we highlight recent findings regarding the distinctions between tissue-resident microglia and MDMs, the identification and characterization of specific TAM subsets, and the dynamic alterations of TAMs during tumor progression and treatment. Last, we briefly discuss the potential of TAM-targeted strategies for combination immunotherapy in rGBM. We anticipate the comprehensive understanding of the diversity and dynamics of TAMs in rGBM will shed light on further improvement of immunotherapeutic efficacy in rGBM.


Persistent Identifierhttp://hdl.handle.net/10722/339128
ISSN
2023 Impact Factor: 5.7
2023 SCImago Journal Rankings: 1.868
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhang, Lingyun-
dc.contributor.authorJiang, Yu-
dc.contributor.authorZhang, Gao-
dc.contributor.authorWei, Shiyou-
dc.date.accessioned2024-03-11T10:34:06Z-
dc.date.available2024-03-11T10:34:06Z-
dc.date.issued2023-09-04-
dc.identifier.citationFrontiers in Immunology, 2023, v. 14-
dc.identifier.issn1664-3224-
dc.identifier.urihttp://hdl.handle.net/10722/339128-
dc.description.abstract<p>Despite tremendous efforts to exploit effective therapeutic strategies, most glioblastoma (GBM) inevitably relapse and become resistant to therapies, including radiotherapy and immunotherapy. The tumor microenvironment (TME) of recurrent GBM (rGBM) is highly immunosuppressive, dominated by tumor-associated macrophages (TAMs). TAMs consist of tissue-resident microglia and monocyte-derived macrophages (MDMs), which are essential for favoring tumor growth, invasion, angiogenesis, immune suppression, and therapeutic resistance; however, restricted by the absence of potent methods, the heterogeneity and plasticity of TAMs in rGBM remain incompletely investigated. Recent application of single-cell technologies, such as single-cell RNA-sequencing has enabled us to decipher the unforeseen diversity and dynamics of TAMs and to identify new subsets of TAMs which regulate anti-tumor immunity. Here, we first review hallmarks of the TME, progress and challenges of immunotherapy, and the biology of TAMs in the context of rGBM, including their origins, categories, and functions. Next, from a single-cell perspective, we highlight recent findings regarding the distinctions between tissue-resident microglia and MDMs, the identification and characterization of specific TAM subsets, and the dynamic alterations of TAMs during tumor progression and treatment. Last, we briefly discuss the potential of TAM-targeted strategies for combination immunotherapy in rGBM. We anticipate the comprehensive understanding of the diversity and dynamics of TAMs in rGBM will shed light on further improvement of immunotherapeutic efficacy in rGBM.<br></p>-
dc.languageeng-
dc.publisherFrontiers Media-
dc.relation.ispartofFrontiers in Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectimmunotherapy-
dc.subjectmicroglia-
dc.subjectmonocyte-derived macrophages-
dc.subjectrecurrent glioblastoma-
dc.subjectsingle-cell-
dc.subjecttumor microenvironment-
dc.titleThe diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma-
dc.typeArticle-
dc.identifier.doi10.3389/fimmu.2023.1238233-
dc.identifier.scopuseid_2-s2.0-85171377005-
dc.identifier.volume14-
dc.identifier.eissn1664-3224-
dc.identifier.isiWOS:001066987000001-
dc.identifier.issnl1664-3224-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats